Chronotherapeutics: Are there meaningful differences among antihypertensive drugs?

Current Hypertension Reports

Volumn 1, Issue 4, 1999, Pages 320-327

  Poirier, Luc ^a   Lefebvre, Jean ^a   Lacourciere, Yves ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT;

BLOOD PRESSURE; BLOOD PRESSURE MONITORING; CHRONOTHERAPY; CIRCADIAN RHYTHM; DRUG EFFECT; HUMAN; HYPERTENSION; PHYSIOLOGY; REVIEW;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CHRONOTHERAPY; CIRCADIAN RHYTHM; HUMANS; HYPERTENSION;

EID: 0033170946     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-999-0040-7     Document Type: Article

References (47)

1. Lemmer B, Labrecque G: Chronopharmacology and chronotherapeutics: definitions and concepts. Chronobiol Int 1987, 4: 319-329.
2. Levi F: Biological rhythms, chronotherapy and nitrates. Ann Cardiol Angeiol 1997, 46: 426-430.
3. Smolensky MH: Chronobiology and chronotherapeutics: applications to cardiovascular medicine. Am J Hypertens 1996, 9:11S-21S.
4. Smolensky MH: Knowledge and attitudes of American physicians and public about medical chronobiology and chronotherapeutics: findings of two 1996 Gallup surveys. Chronobiol Int 1998, 15: 377-394.
5. Mulcahy D, Keegan J, Cunningham D, et al.: Circadian variation of total ischemic burden and its alteration with antianginal agents Lancet 1988, 2: 755-759.
6. Fox K, Mulcahy D, Keegan J, et al.: Circadian patterns of myocardial ischemia. Am Heart J 1989, 118: 1084-1087.
7. Argentino C, Toni D, Rasura M, et al.: Circadian variation in the frequency of ischemic stroke. Stroke 1990, 12: 387-389.
8. Marler JR, Price TR, Clark GL, et al.: Morning increase in onset of ischemic stroke. Stroke 1989, 20: 473-476.
9. Willich SN, Levy D, Rocco MB, et al.: Circadian variation in the incidence of sudden cardiac death in the Framingham Heart Study population. Am J Cardiol 1987, 60: 801-806.
10. Muller JE, Stone PH, Turi ZG, et al.: Circadian variation in the frequency of onset of acute myocardial infarction. N Engl J Med 1985, 313: 1315-1322.
11. Muller JE, Toffler GH, Stone PH: Circadian variation and triggers of onset of acute cardiovascular disease. Circulation 1989, 79: 733-743.
12. Staessen J, Bulpitt CJ, O'Brien E, et al.: The diurnal blood pressure profile: a population study. Am J Hypertens 1992, 5: 386-392.
13. Punzi HA: Why ambulatory blood pressure monitoring? Am J Health Syst Pharm 1998, 55:S12-S16.
14. Waeber B, Rutschmann B, Nüssberger J, et al.: Evaluation of antihypertensive therapy: discrepancies between office and ambulatory recorded blood pressure. J Hypertens 1991, 9:S53-S56.
15. The Scientific Committee: Consensus document on noninvasive ambulatory blood pressure monitoring. J Hypertens 1990, 8:S135-S140.
16. Neutel J, Smith D, Ram C: Application of ambulatory blood pressure monitoring in differentiating between antihypertensive agents. Am J Med 1993, 94: 181-187.
17. Verdecchia P, Porcellati C, Schillaci G: Ambulatory blood pressure: an independant predictor of prognosis in essential hypertension. Hypertension 1994, 24: 793-801.
18. Perloff D, Sokolow M, Cowan R, et al.: Prognostic value of ambulatory blood pressure measurements: further analyses. J Hum Hypertens 1989, 7:S3-S10. (Pubitemid 19170276)
19. Perloff D, Sokolow M, Cowan R: The prognostic value of ambulatory blood pressure. JAMA 1983, 249: 2792-2798.
20. Mancia G, Zanchetti A, Agebiti-Rosei E, et al.: Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy. Circulation 1997, 95: 1464-1470.
21. Timio M, Lalli S, Venanzi S: Renal damage and night-time blood pressure in uremic, treated hypertensive patients: a 3 years prospective study. Proceedings of the Sixth European Meeting on Hypertension: 4-7 June 1993, Milan. J Hypertens 1993, 11:S490.
22. White WB, Mehrotra DV, Black HR, et al.: Effects of controlledonset extended-release verapamil on nocturnal blood pressure (dippers versus nondippers). COER-Verapamil Study Group. Am J Cardiol 1997, 80: 469-74.
23. Carter BL: Optimizing delivery systems to tailor pharmacotherapy to cardiovascular circadian events. Am J Health Syst Pharm 1998, 55:S17-S23.
24. Anwar YA, White WB: Chronotherapeutics for cardiovascular disease. Drugs 1998, 55: 631-643.
25. Palatini P, Racioppa A, Raule A, et al.: Effect of timing of administration on the plasma ACE inhibitor activity and the antihypertensive effect of quinapril. Clin Pharmacol Ther 1992, 52: 378-383.
26. Greminger P, Suter PM, Holm D, et al.: Morning versus evening administration of nifedipine gastrointestinal therapeutic system in the management of essential hypertension. Clin Investig 1994, 72: 864-869.
27. Lemmer B: Differential effects of antihypertensive drugs on circadian rhythm in blood pressure from the chronobiological point of view. Blood Press Monit 1996, 1: 161-169.
28. Fogari R, Malocco E, Tettamanti F, et al.: Evening versus morning isradipine sustained release in essential hypertension: a double-blind study with 24-hour ambulatory monitoring. Br J Clin Pharmacol 1993, 35: 51-54.
29. Lemmer B, Sasse U, Witte K, et al.: Pharmacokinetics and cardiovascular effects of a new sustained-release formulation of diltiazem [abstract]. Arch Pharmacol 1994, 349S:R141.
30. Meilhac B, Mallion JM, Carre A, et al.: Étude de l'influence de l'horaire de la prise sur l'effet antihypertenseur et la tolérance de la nitrendipine chez des patients hypertendus essentiels légers à modérés. Therapie 1992, 47: 205-210.
31. Umeda T, Naomi S, Iwaoka K, et al.: Timing of administration of am antihypertensive drug in the treatment of essential hypertension. Hypertension 1994, 23: 1211-1214.
32. Palatini P, Mos L, Mormino P, et al.: Effect of evening versus morning benazepril on 24-hour blood pressure: a comparative study with continuous intraarterial monitoring. Int J Clin Pharmacol Ther 1993, 31: 295-300.
33. Witte K, Weisser K, Neubeck M, et al.: Cardiovascular effects, pharmacokinetics, and converting enzyme inhibition o enalapril after morning versus evening administration. Clin Pharmacol Ther 1993, 54: 177-186.
34. Conte G, Rigon N, Perrone A: Application of chronotherapy to cardiovascular disease. Recenti Prog Med 1998, 89: 465-469.
35. Kario K, Matsuo T, Kobayashi H, et al.: Nocturnal fall of blood pressure and silent cerebrovascular damage in elderly hypertensive patients: advanced silent cerebrovascular damage in extreme dippers. Hypertension 1996, 27: 130-135.
36. Burt VL, Whelton P, Roccella EJ, et al.: Prevalence of hypertension in the US adult population: results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension 1995, 25: 305-313.
37. Chockalingam A, Fodor JG: Treatment of raised blood pressure in the population: the Canadian experience. Am J Hypertens 1998, 11: 747-749.
38. Mancia G, Cattaneo BM, Omboni S, et al.: Clinical benefits of a consistent reduction in blood pressure. J Hypertens Suppl 1998, 16:S35-S39. (Pubitemid 28521816)
39. WHO/ISH Guidelines Sub-Committee. Guidelines for the management of mild hypertension: memorandum from a World Health Organization/International Society of Hypertension meeting. J Hypertens 1993, 11: 905-918.
40. Zannad F, Matzinger A, Larché J: Trough/peak ratios of once daily angiotensin converting enzyme inhibitors and calcium antagonists. Am J Hypertens 1996, 9: 633-643.
41. Lefebvre J, Poirier L, Archambault F, et al.: Comparative effects of felodipine ER, amlodipine and nifedipine GITS on 24h blood pressure control and trough to peak ratios in mild to moderate ambulatory hypertension: a forced titration study. Can J Cardiol 1998, 14: 682-688.
42. Lacourciere Y, Poirier L, Lefebvre J, et al.: Clinical efficacy of force titrated doses of diltiazem extended-release: a placebo-controlled study. Am J Hypertens 1995, 8: 282-286.
43. Lacourciere Y, Lefebvre J, Poirier L, et al.: Treatment of ambulatory hypertensives with nebivolol or hydrochlorothiazide alone and in combination: a randomized, double- blind, placebo- controlled, factorial-design trial. Am J Hypertens 1994, 7: 137-45.
44. Lacourciere Y, Poirier L, Dion D, et al.: Antihypertensive effect of isradipine administered once or twice daily on ambulatory blood pressure. Am J Cardiol 1990, 65: 467-72.
45. Black HR, Elliott WJ, Neaton JD, et al.: Rationale and design for the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) Trial. Control Clin Trials 1998, 19: 370-390.
46. White WB: A chronotherapeutic approach to the management of hypertension. Am J Hypertens 1996, 9:29S-33S.
47. White WB, Black HR, Weber MA, et al.: Comparison of effects of controlled onset extended release verapamil at bedtime and nifedipine gastrointestinal therapeutic system on arising on early morning blood pressure, heart rate, and the heart rate-blood pressure product. Am J Cardiol 1998, 81: 424-431.